Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Robert S. who wrote (7775)	11/19/1998 8:40:00 PM
From: Starlight	Respond to of 17367

Here are current statistics from the MMWR (Morbidity and Mortality Weekly Report): For the 4 weeks ending Nov. 14, 156 meningococcal infections were reported. The cumulative total for 1998 is 2306. The cumulative total for the same time period in 1997 was 2799 cases.

To: Robert S. who wrote (7775)	11/19/1998 11:54:00 PM
From: Robert K.	Read Replies (1) \| Respond to of 17367

I do not accept that bpi neutralizes cytokines. It attenuates certain cytokines. Which cytokines does it attenuate and what are their roles? Under what conditions? How about that tnf. In complement its numero uno in my book. Eicosanoids and kinins I have no idea, but doubt any effect. Fibrinolytic, you didnt even mention. Questions back at you. Are you aware of any product that affects more inflamatory mediators than bpi? Is bpi a defacto cocktail? If bpi ever does get to market will they test it with anti tnf monoclonals? Ha1a or e5? Hey Rick, when you get to this one why dont you throw in a comment too.